title: Should We Still Administer Prophylactic Rectal NSAIDs to Average-Risk Patients Undergoing ERCP?
authors.affiliation: Division of Gastroenterology & Hepatology, Medical University of South Carolina, Charleston, South Carolina.
authors.forename: B Joseph
authors.initials: BJ
authors.lastname: Elmunzer
authors.affiliation: Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.
authors.forename: Lydia D
authors.initials: LD
authors.lastname: Foster
authors.affiliation: Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.
authors.forename: Valerie
authors.initials: V
authors.lastname: Durkalski
mesh_terms: D000285:Administration, Rectal; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002760:Cholangiopancreatography, Endoscopic Retrograde; D006801:Humans; D007213:Indomethacin; D010195:Pancreatitis; D012306:Risk
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007213:Indomethacin